PHASE I-II STUDY OF F17752 IN PATIENTS WITH ADVANCED SOLID TUMOURS

PIERRE FABRE MEDICAMENT0 个研究点目标入组 122 人开始时间: 2015年9月16日最近更新: 2017年10月2日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: PIERRE FABRE MEDICAMENT
入组人数: 122

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Histologically or cytologically confirmed advanced solid tumour. Patients with solid tumours known to present with Alk, ROS or Trk rearrangement will be preferentially recruited
•Refractory to available therapies or for whom no standard of care therapy is available
•Cohort 1: NSCLC patients whose tumours exhibit Alk or ROS rearrangement and who are resistant to at least one prior Alk inhibitor, or other actionable targets pertinent to F17752 activity,
•Cohort 2: patients with colon cancer whose tumours exhibit Trk rearrangement, or other actionable targets pertinent to F17752 activity.
•Criteria common to phase I and phase II parts
•1. Tumour tissue available for analysis. If sufficient tissue is not available, patients must undergo a biopsy to obtain adequate samples. In cohort 1 for which failure to prior Alk inhibitor is required, tumour tissue must be obtained following failure to prior therapy,
•2. Measurable disease according to RECIST (version 1.1),
•3. Female or male, 18 years of age or older,
•4. WHO performance status 5. Anticipated life expectancy > or=12 weeks,
•6. Adequate haematological function defined as ANC > or= 1.5 x 109/L, platelet count > or= 100 x 109/L and haemoglobin > or= 9 g/dL,
•7. Adequate liver function tests defined as total bilirubin 8. Adequate renal function defined as serum creatinine 9. Normal QT interval on electrocardiogram performed at baseline
•10.Women of childbearing potential must be using a medically accepted method of contraception (i.e. oral contraceptives, intrauterine devices) to avoid pregnancy during the 2 months preceding the start of study treatment, throughout the study period and for up to 3 months after the last dose of study treatment in such a manner that the risk of pregnancy is minimized. Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of study treatment,
•11. Fertile men must be using an effective method of birth control throughout the study period and up to 3 months after the last dose of study drug if their partners are women of childbearing potential,
•12. The patient must have access to social insurance if applicable in the local regulations,
•13. Informed written consent,
•14. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 122
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 122

排除标准

•for Phase I and Phase II
•1. Major surgery, radiotherapy or systemic anti-cancer therapy within 3 weeks of starting study treatment ; only for systemic anticancer therapy, within 2 weeks in cohort 1,
•2. Patients central nervous system metastases unless the patient has completed local therapy, is stable for at least 4 weeks on CT-scan without evidence of cerebral oedema and has no requirement for corticosteroids or anticonvulsivants,
•3. Current active infection; any concurrent, uncontrolled medical disorder, making implementation of the protocol difficult,
•4. Known HIV infection,
•5. History of another malignancy within the past five years except basal cell carcinoma of the skin or carcinoma in situ of the cervix, and surgically-treated-only or lobular carcinoma in situ of the breast diagnosed more than 5 years ago,
•6. Active heart disease including myocardial infarction within the previous 6 months, symptomatic coronary artery disease, arrhythmia not controlled by medication or uncontrolled congestive heart failure,
•7. Known malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of F17752,
•8. Concurrent treatment with any other anti-cancer therapy,
•9. Participation in another trial of an investigational agent within 30 days before study entry and during the study,
•10. Known hypersensitivity to drugs with similar chemical structures,
•11. Congenital lactose intolerance,
•12. Pregnant or lactating women, women with positive pregnancy test at inclusion.

研究者

发起方

PIERRE FABRE MEDICAMENT

相似试验

进行中（未招募）

1 期

A Study of FT-2102 in Patients with Advanced Solid Tumors and GliomasAdvanced Solid Tumors and Gliomas with an IDH1 MutationMedDRA version: 20.0Level: PTClassification code 10018338Term: GliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073073Term: Hepatobiliary cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10073077Term: Intrahepatic cholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-001796-21-ESFORMA Therapeutics, Inc.200

进行中（未招募）

1 期

A Study of FT-2102 in Patients with Advanced Solid Tumors and GliomasAdvanced Solid Tumors and Gliomas with an IDH1 MutationMedDRA version: 20.0Level: PTClassification code 10018338Term: GliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10073073Term: Hepatobiliary cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10073077Term: Intrahepatic cholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-001796-21-GBForma Therapeutics, Inc.200

进行中（未招募）

1 期

EUCTR2018-001796-21-FRFORMA Therapeutics, Inc.200

未知

2 期

A M117101 phase II study in patients with primary palmar hyperhidrosisprimary palmar hyperhidrosis

JPRN-jRCT2080222374Maruho Co.,Ltd.

进行中（未招募）

1 期

Ipilimumab, nivolumab and tocilizumab in pretreated patients with advanced pancreatic cancer.Pretreated patients with advanced pancreatic cancer.MedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864

EUCTR2019-004438-40-DKDepartment of Oncology, Herlev & Gentofte Hospital30